
This Accenture survey explores how pharmaceutical companies can better engage with healthcare providers (HCPs) in a post-COVID-19 landscape.
The study, involving 720 HCPs across six countries, reveals that while pharma has improved its communication, there's still a significant gap in understanding HCPs' evolving needs and those of their patients.
A key finding is that HCPs reward companies that demonstrate this understanding with more time and attention, particularly as many now have fewer patient visits.
Ultimately, HCPs highly value meaningful connections that blend virtual and in-person interactions, prioritising content that directly aids patient care and decision-making, such as data-driven recommendations.
Related Articles
Beyond the Mass Email: The Imperative of Personalization in Pharma
Why HCPs are tuning out generic communications and how personalization is transforming engagement.
Pharma Marketing: What's Working for HCPs in 2025
Key insights from pharma marketing leaders on effective HCP engagement strategies.
How Omnichannel is Transforming Pharma Engagement
The digital transformation journey and its impact on healthcare provider relationships.